We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · August 06, 2021

Factors Predicting Progression in Patients With Ph+ ALL in Complete Molecular Response Within 3 Months of TKI Therapy



Additional Info

Prognostic Factors for Progression in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in Complete Molecular Response Within 3 Months of Therapy With Tyrosine Kinase Inhibitors
Cancer 2021 Aug 01;127(15)2648-2656, K Sasaki, HM Kantarjian, NJ Short, B Samra, JD Khoury, R Kanagal Shamanna, M Konopleva, N Jain, CD DiNardo, R Khouri, G Garcia-Manero, TM Kadia, WG Wierda, IF Khouri, P Kebriaei, RS Mehta, RE Champlin, R Garris, CM Cheung, N Daver, PA Thompson, M Yilmaz, F Ravandi, E Jabbour

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading